HighTower Advisors
EBS icon

HighTower Advisors’s Emergent Biosolutions EBS Stock Holding History

HighTower Advisors’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,185
Closed -$295K – 3215
2021
Q1 		$295K Buy
3,185
+73
+2% +$7.48K ﹤0.01% 2315
2020
Q4 		$280K Buy
3,112
+431
+16% +$39.6K ﹤0.01% 1985
2020
Q3 		$278K Sell
2,681
-2,769
-51% -$298K ﹤0.01% 1873
2020
Q2 		$430K Buy
5,450
+11
+0.2% +$820 ﹤0.01% 1540
2020
Q1 		$314K Buy
5,439
+586
+12% +$33.8K ﹤0.01% 1539
2019
Q4 		$262K Buy
4,853
+1,018
+27% +$55.2K ﹤0.01% 1801
2019
Q3 		$201K Buy
+3,835
New +$179K ﹤0.01% 2055
2018
Q4 		– Sell
-5,344
Closed -$359K – 2241
2018
Q3 		$359K Buy
+5,344
New +$312K ﹤0.01% 1636

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighTower Advisors's EBS Position: Q2 2021 in Review

HighTower Advisors sold out of Emergent Biosolutions (EBS) in Q2 2021, closing a stake of 3,185 shares — an estimated $295K sold.

HighTower Advisors first reported a position in EBS in Q3 2018 and held it in 8 quarters. The position peaked at $430K in Q2 2020. 290 funds tracked by Wall St. Rank hold EBS as of Q2 2021.

  • HighTower Advisors reported no remaining Emergent Biosolutions position as of Q2 2021 after selling out during the quarter.
  • HighTower Advisors sold 3,185 Emergent Biosolutions shares in Q2 2021, an estimated $295K.
  • HighTower Advisors first reported a position in Emergent Biosolutions in Q3 2018 and held it in 8 quarters.
  • HighTower Advisors's Emergent Biosolutions position peaked at $430K in Q2 2020.
  • 290 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2021.

Based on HighTower Advisors's 13F filing for Q2 2021, filed 6 Aug 2021.